Immunotherapy is set to become the default treatment for the vast majority of lung cancer patients after a clinical trial from drugmaker Merck showed that adding its novel medicine to chemotherapy boosted survival.
制藥公司默克(Merck)的一項(xiàng)臨床試驗(yàn)顯示，其研發(fā)的新藥物聯(lián)合化療會(huì)提高肺癌患者存活率，免疫療法將成為絕大多數(shù)肺癌患者的默認(rèn)療法。
您已閱讀9%（280字），剩余91%（2918字）包含更多重要信息，訂閱以繼續(xù)探索完整內(nèi)容，并享受更多專屬服務(wù)。